Corvus Pharmaceuticals (CRVS) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on June 11, 2026, with shareholders able to vote online, by phone, or by mail.

• Shareholders of record as of April 16, 2026, are entitled to vote on three main proposals: election of two Class I directors, ratification of the independent auditor, and a non-binding advisory vote on executive compensation.

• The board recommends voting in favor of all three proposals.

• Proxy materials are primarily distributed electronically to reduce costs and environmental impact.

Voting matters and shareholder proposals

• Proposal 1: Elect two Class I directors (Richard A. Miller, M.D. and Linda S. Grais, M.D., J.D.) for terms expiring at the 2029 annual meeting.

• Proposal 2: Ratify PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Proposal 3: Approve, on a non-binding advisory basis, the compensation of named executive officers.

• Shareholders may also vote on any other business properly brought before the meeting.

• Deadlines and procedures for submitting shareholder proposals for the 2027 annual meeting are specified.

Board of directors and corporate governance

• The board is divided into three classes, with staggered three-year terms; currently consists of seven directors.

• All directors except the CEO are considered independent under Nasdaq rules.

• The board has audit, compensation, and nominating/corporate governance committees, each with defined responsibilities and independent members.

• Corporate governance guidelines, code of business conduct and ethics, and insider trading policies are in place.

• Board and committee attendance exceeded 75% for all members in the last fiscal year.